Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Exebacase

Generic Name: Exebacase

Drug Type: Biotech

CAS Number: 1404122-92-4

Unique Ingredient Identifier: 67F0M5CY5Y

Overview

Exebacase is under investigation in clinical trial NCT03163446 (Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia).

Background

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Expanded Access Study of Exebacase in COVID-19 Patients With Persistent MRSA Bacteremia

Posted: 2020/10/22

Sponsor:

ContraFect

ID:NCT04597242

Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase

Phase 3

Terminated

Posted: 2019/11/13

Sponsor:

ContraFect

ID:NCT04160468

A Placebo-Controlled, Dose-Escalating Study to Examine the Safety and Tolerability of Single Intravenous Doses of CF-301 in Healthy Subjects

Phase 1

Completed

Posted: 2015/05/08

Sponsor:

ContraFect

ID:NCT02439359

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy